This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    I6A-MC-CBBD
Previous Study | Return to List | Next Study

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Eli Lilly and Company
Sponsor:
Collaborator:
Sarah Cannon Development Innovations
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT02407054
First received: March 30, 2015
Last updated: April 21, 2017
Last verified: April 2017
  Purpose
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

Condition Intervention Phase
Prostate Cancer Metastatic Drug: LY3023414 Drug: Enzalutamide Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Baseline to Measured Progressive Disease or Death from Any Cause (Approximately 6 Months) ]

Secondary Outcome Measures:
  • Time to Disease Progression [ Time Frame: Baseline to Objective Disease Progression (Approximately 6 Months) ]
  • Percent Change from Baseline to 12 Weeks in Prostate Specific Antigen (PSA) [ Time Frame: Baseline, 12 Weeks ]
  • PK: Area Under the Concentration Curve (AUC) of LY3023414 and Enzalutamide [ Time Frame: Predose Cycle 1 to Cycle 3 Day 1 (Approximately 2 Months) ]
  • Proportion of Participants with a Complete or Partial Response (Overall Response Rate) [ Time Frame: Baseline to Second Measured Complete Response or Partial Response (Approximately 4 Months) ]

Estimated Enrollment: 144
Study Start Date: April 2015
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY3023414 + Enzalutamide
Lead In- LY3023414 orally twice daily in first week for pharmacokinetics (PK); thereafter LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Randomization- LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
Drug: LY3023414
Administered orally
Drug: Enzalutamide
Administered orally
Active Comparator: Enzalutamide + Placebo
Enzalutamide orally once daily in combination with matching LY3023414 placebo orally twice daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
Drug: Enzalutamide
Administered orally
Drug: Placebo
Administered orally

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan.
  • Prostate cancer progression documented by PSA and/or radiographic progression according to prostate cancer working group 2 (PCWG2).
  • Prior abiraterone treatment completed at least 4 weeks prior to cycle 1 day 1. Participants must have failed prior abiraterone treatment.
  • Surgically or medically castrated, with testosterone levels of < 50 nanograms/deciliter.
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
  • Ability to swallow the study drugs whole.
  • Adequate hematologic function.
  • Adequate coagulation parameters, defined as international normalization ratio (INR) ≤ 2.
  • Availability of tumor tissue from any time since diagnosis of prostate cancer disease. If no tumor samples are available the participant might still be eligible following discussion between the investigator and the medical monitor.

Exclusion Criteria:

  • Prior cytotoxic chemotherapy, immunotherapy, a PI3K/AKT/mTOR agent (including TORC1 and TORC2 inhibitors), or RA 223 dichloride for the treatment of castration resistant prostate cancer (CRPC). Participants may have received docetaxel in the hormone-sensitive setting.
  • Prior investigational new generation potent anti-androgen therapy (such as ARN 509).
  • Prior treatment with enzalutamide.
  • Pathological finding consistent with small cell carcinoma of the prostate.
  • Prior systemic treatment with an azole drug (fluconazole, itraconazole) within 4 weeks of cycle 1 day 1.
  • Known brain metastasis.
  • History of (a) seizure or any condition that may predispose to seizure (prior cortical stroke or significant brain trauma); (b) loss of consciousness or transient ischemic attack within 12 months prior to day 1 of cycle 1.
  • Uncontrolled hypertension (systolic blood pressure [BP] ≥ 160 millimeters of mercury [mmHg] or diastolic BP ≥ 95 mmHg).
  • Have serious pre-existing medical conditions (at the discretion of the investigator).
  • Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
  • Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetics as documented by hemoglobin A1c <7%.
  • Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, grade ≥2 diarrhea, and malabsorption syndrome).
  • Have a history of New York Heart Association (NYHA) Class ≥3, QTc interval > 480 milliseconds (ms) on screening electrocardiogram (ECG) per Friderica's formula, unstable angina, or myocardial infarction (MI) in 6 months prior to study drug administration.
  • Clinically significant electrolyte imbalance ≥ grade 2.
  • Currently receiving treatment with therapeutic doses of warfarin sodium.
  • Have initiated treatment with bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤28 days prior to day 1 of cycle 1.
  • Concurrent serious infections requiring parenteral antibiotic therapy.
  • Have a second primary malignancy that in the judgment of the investigator and medical monitor may affect the interpretation of results.
  • Have an active, known fungal, bacterial, and/or known viral infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02407054

Contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

  Show 50 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Sarah Cannon Development Innovations
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02407054     History of Changes
Other Study ID Numbers: 15798
I6A-MC-CBBD ( Other Identifier: Eli Lilly and Company )
Study First Received: March 30, 2015
Last Updated: April 21, 2017

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 21, 2017